177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

Clin Nucl Med. 2019 Dec;44(12):978-980. doi: 10.1097/RLU.0000000000002824.

Abstract

We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.

Publication types

  • Case Reports

MeSH terms

  • Antigens, Surface / metabolism*
  • Carcinoma, Neuroendocrine / metabolism
  • Carcinoma, Neuroendocrine / pathology*
  • Carcinoma, Neuroendocrine / radiotherapy*
  • Glutamate Carboxypeptidase II / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Prostatic Neoplasms, Castration-Resistant / metabolism
  • Prostatic Neoplasms, Castration-Resistant / pathology*
  • Prostatic Neoplasms, Castration-Resistant / radiotherapy*
  • Receptors, Somatostatin / metabolism

Substances

  • Antigens, Surface
  • Organometallic Compounds
  • Receptors, Somatostatin
  • lutetium Lu 177 dotatate
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II
  • Octreotide